Vaccines are an especially risky proposition for pharmaceutical manufacturers since the costs are higher than for other types of drugs and demand could drop drastically once a crisis is over.
By
MIT study explores the key factors behind patient outcomes in clinical trials evaluating new treatments for non-small-cell lung cancer.
By
The studies describe new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines.
By
MIT Sloan and CSAIL researchers apply artificial intelligence techniques to one of the largest datasets of clinical trial outcomes to handicap the drug and device approval process
By
The MIT Laboratory for Financial Engineering (LFE) and Informa Pharma Intelligence announced a new initiative, Project ALPHA (Analytics for Life-sciences Professionals and Healthcare Advocates).
Researchers launched an in-house Data Science and Artificial Intelligence (DSAI) challenge to beat MIT’s machine-learning models for predicting clinical trial outcomes. The results are now available.
By
Rajiv Shah, president of The Rockefeller Foundation and former administrator of USAID, believes in leveraging the passion of individuals to affect large-scale change in society.
By
Over 1,300 Sloanies and their guests returned to campus in early June to attend MIT Sloan Reunion 2023.
For decades, MIT Sloan Professor Lotte Bailyn has been calling for changes in the way work is organized -- often in ways that have proven prescient.
By
During September's iLead Speaker Series event, Analysis Group’s Martha Samuelson, SF ’86, and Rebecca Kirk Fair, MBA ’02, discussed their professional journeys, as well as the culture and leadership of their firm.
